Retrospective Review for Prevalence and Survival in Metastatic Breast Cancer with Brain Metastasis in Two Patient Cohorts: One Collected 2000-2005 and the Second Collected 2006-2011 — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Retrospective Review for Prevalence and Survival in Metastatic Breast Cancer with Brain Metastasis in Two Patient Cohorts: One Collected 2000-2005 and the Second Collected 2006-2011
Department of Nursing, Excelsior College, Albany, NY, USA
,
Department of Mathematics, Rochester Institute of Technology, Rochester, NY, USA
,
OncoGambit, Irvine, CA, USA
1 Department of Nursing, Excelsior College, Albany, NY, USA
2 Department of Mathematics, Rochester Institute of Technology, Rochester, NY, USA
Purpose: To determine whether the new treatments for breast cancer CNS metastases improve survival by comparing the survival between two cohorts: 2000-2005 and 2006-2011. Patients and Methods: A retrospective, comparative, correlational chart review was performed. Data from 172 women diagnosed with CNS metastases between 2000 and 2011, was evaluated. Results: Approximately 10% of patients diagnosed with invasive breast cancer between 2000 and 2011 developed CNS metastases. The cohort was separated into four groups: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2+ (ER -, PR-, HER2+) and TN (ER-, PR-, HER2-). There was a statistically significant difference in the overall survival between luminal A and luminal B (5.55 months vs. 15.3 months, respectively, p = 0.048). There was also a statistically significant difference in the overall survival between luminal B and TN (15.3 months vs. 7.49 months, respectively, p = 0.0181). There was no significant difference in overall survival between luminal B and HER2+ (15.3 months vs. and 10.98 months, respectively, p = 0.105), TN and HER2+ (7.49 months vs. 10.98 months, respectively, p = 0.514), and between luminal A and TN or HER2+ (5.55 months vs. 7.49 months, respectively, p = 0.428, or 5.55 months vs. 10.98 months, respectively, p = 0.491). Overall median survival of the patients in 2000-2005 and 2006-2011 were 6.64 months vs. 10.58 months, respectively (p = 0.0592). Conclusion: The results of our study showed that despite the new therapies there is little improvement in survival for brain metastasis in breast cancer.
Lin, N.U., Bellon, J.R. and Winer, E.P. (2004) CNS Metastases in Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22, 3608-3617. https://doi.org/10.1200/JCO.2004.01.175
Gil-Gil, M.J., Martinez-Garcia, M., Sierra, A., Conesa, G., Del Barco, S., Gonzalez-Jimenez, S., et al. (2014) Breast Cancer Brain Metastases: A Review of the Literature and a Current Multidisciplinary Management Guideline. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 16, 436-446. https://doi.org/10.1007/s12094-013-1110-5
Weil, R.J., Palmieri, D.C., Bronder, J.L., Stark, A.M. and Steeg, P.S. (2005) Breast Cancer Metastasis to the Central Nervous System. The American Journal of Pathology, 167, 913-920. https://doi.org/10.1016/S0002-9440(10)61180-7
Sim, H.W., Morris, P.G., Patil, S. and Khasraw, M. (2014) Brain Metastases in Breast Cancer. Expert Review of Anticancer Therapy, 14, 173-183. https://doi.org/10.1586/14737140.2014.863468
Barnholtz-Sloan, J.S., Sloan, A.E., Davis, F.G., Vigneau, F.D., Lai, P. and Sawaya, R.E. (2004) Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22, 2865-2872. https://doi.org/10.1200/JCO.2004.12.149
Gavrilovic, I.T. and Posner, J.B. (2005) Brain Metastases: Epidemiology and Pathophysiology. Journal of Neuro-Oncology, 75, 5-14. https://doi.org/10.1007/s11060-004-8093-6
Bendell, J.C., Domchek, S.M., Burstein, H.J., Harris, L., Younger, J., Kuter, I., et al. (2003) Central Nervous System Metastases in Women Who Receive Trastuzumab-Based Therapy for Metastatic Breast Carcinoma. Cancer, 97, 2972-2977. https://doi.org/10.1002/cncr.11436
Brufsky, A.M., Mayer, M., Rugo, H.S., Kaufman, P.A., Tan-Chiu, E., Tripathy, D., et al. (2011) Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from RegistHER. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17, 4834-4843. https://doi.org/10.1158/1078-0432.CCR-10-2962
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M.C., Voduc, D., Speers, C.H., et al. (2010) Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 3271-3277. https://doi.org/10.1200/jco.2009.25.9820
Lin, N.U., Vanderplas, A., Hughes, M.E., Theriault, R.L., Edge, S.B., Wong, Y.N., et al. (2012) Clinicopathologic Features, Patterns of Recurrence, and Survival among Women with Triple-Negative Breast Cancer in the National Comprehensive Cancer Network. Cancer, 118, 5463-5472. https://doi.org/10.1002/cncr.27581
Kondziolka, D., Kano, H., Harrison, G.L., Yang, H.C., Liew, D.N., Niranjan, A., et al. (2011) Stereotactic Radiosurgery as Primary and Salvage Treatment for Brain Metastases from Breast Cancer. Clinical Article. Journal of Neurosurgery, 114, 792-800. https://doi.org/10.3171/2010.8.JNS10461
Akyurek, S., Chang, E.L., Mahajan, A., Hassenbusch, S.J., Allen, P.K., Mathews, L.A., et al. (2007) Stereotactic Radiosurgical Treatment of Cerebral Metastases Arising from Breast Cancer. American Journal of Clinical Oncology, 30, 310-314. https://doi.org/10.1097/01.coc.0000258365.50975.f6
Jung, S.Y., Rosenzweig, M., Sereika, S.M., Linkov, F., Brufsky, A. and Weissfeld, J.L. (2012) Factors Associated with Mortality after Breast Cancer Metastasis. Cancer Causes & Control, 23, 103-112. https://doi.org/10.1007/s10552-011-9859-8
Niikura, N., Hayashi, N., Masuda, N., Takashima, S., Nakamura, R., Watanabe, K., et al. (2014) Treatment Outcomes and Prognostic Factors for Patients with Brain Metastases from Breast Cancer of Each Subtype: A Multicenter Retrospective Analysis. Breast Cancer Research and Treatment, 147, 103-112. https://doi.org/10.1007/s10549-014-3090-8
Wadasadawala, T., Gupta, S., Bagul, V. and Patil, N. (2007) Brain Metastases from Breast Cancer: Management Approach. Journal of Cancer Research and Therapeutics, 3, 157-165. https://doi.org/10.4103/0973-1482.37409
Ushio, A., Sawaki, M., Fujia, T., Hattori, M., Kondo, N., Horio, A., Gondou, N., Iwata, H., et al. (2012) Clinicopathological Analysis of Breast Cancer Patients with Brain Metastases. San Antonio Breast Cancer Symposium; San Antonio.
Dawood, S., Broglio, K., Esteva, F.J., Yang, W., Kau, S.W., Islam, R., et al. (2009) Survival among Women with Triple Receptor-Negative Breast Cancer and Brain Metastases. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 20, 621-627. https://doi.org/10.1093/annonc/mdn682
Meier, C.A., Vaz-Luis, I., Seah, D., Macrae, E.M., Burstein, H.J., Sohl, J., Arvold, N.D., Winer, E.P., Lin, N.U., et al. (2013) Impact of Tumor Subtype on Clinical Features, Treatment, and Clinical Outcomes among Breast Cancer Patients with Central Nervous System Disease. San Antonio Breast Cancer Symposium; San Antonio.
Bartsch, R., Berghoff, A., Bago-Horvath, Z., DeVries, C., Dubsky, P., Pluschnig, U., Rudas, M., Rottenfusser, A., Fitzal, F., Dieckmann, K., Mader, R.M., Gnant, M., Zielinski, C.C., Steger, G.G., et al. (2011) Brain Metastasis Free Survival (BMFS) Differs between Breast Cancer Subtypes. San Antonio Breast Cancer Symposium, San Antonio. https://doi.org/10.1158/0008-5472.sabcs11-p4-17-05
Hines, S.L., Rana, F., McNeil, R.B., Peterson, J., Vallow, L., Tan, W., et al. (2009) Survival Differences by Ethnicity in Triple-Negative Breast Cancer and Brain Metastases. American Society of Clinical Oncology, Chicago.